Early detection of chronic kidney disease in primary care provides a significant opportunity to avoid complications and slow the loss of renal function. Topline guidance, here.
Guidance for primary care physicians on the diagnosis of chronic kidney disease (CKD), including identifying patients at highest risk for progression to kidney failure, is offered by the National Kidney Disease Program and the Kidney Disease Outcomes Quality Initiative.
For a concise summary of key points, click through the slides below.
Sotagliflozin in Patients with Type 1 Diabetes and CKD to be Discussed at October FDA AdComm Meeting
October 14th 2024Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.
Tirzepatide Real-World Benefit Found Greater for CV, Renal Outcomes vs GLP-1 RAs in Adults with T2D
August 12th 2024In a head-to-head real world study, tirzepatide compared with semaglutide resulted in 42%, 20%, and 46% reduced risks for all-cause mortality and major adverse CV and renal events, respectively.